Filing Details
- Accession Number:
- 0000899243-16-016850
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-03-29 19:08:52
- Reporting Period:
- 2016-03-28
- Filing Date:
- 2016-03-29
- Accepted Time:
- 2016-03-29 19:08:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1609809 | Seres Therapeutics Inc. | MCRB | Pharmaceutical Preparations (2834) | 274326290 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1643734 | D. Eric Shaff | C/O Seres Therapeutics, Inc. 215 First Street Cambridge MA 02142 | Cfo And Evp | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-03-28 | 5,473 | $7.79 | 5,473 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-03-28 | 5,473 | $24.07 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2016-03-28 | 5,473 | $0.00 | 5,473 | $7.79 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
257,219 | 2024-12-08 | No | 4 | M | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.